文献速递头颈外科

立体定向体部放疗用于不适合手术的头颈癌患者

Stereotactic body radiotherapy for medically unfit patients with cancers to the head and neck.
PubMed 文献 · Head Neck · 2020-03-21

仅1例发生急性4级毒性,2例发生晚期4级毒性。

要点

  • SBRT对不适合手术的头颈癌患者可获得12个月局部控制率78.2%-85.8%。
  • 严重毒性罕见,仅1例急性4级和2例晚期4级毒性。

核心结论

  • 对于无法耐受长时间放疗的虚弱头颈癌患者,SBRT是一种有效的治疗选择,可获得较好的局部控制。

主要发现

  • 队列包括初治原发头颈癌48例、复发未放疗头颈癌19例、寡转移非头颈原发17例、再程放疗头颈癌33例。
  • 仅1例发生急性4级毒性,2例发生晚期4级毒性。

临床怎么用

  • 对于因医学原因不适合手术且无法耐受长疗程放疗的头颈癌患者,可考虑采用SBRT(35-50 Gy/4-6次)作为替代治疗。

局限性

  • 本研究为单中心回顾性研究,样本量有限,随访时间较短,需前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A single institutional experience of stereotactic body radiation therapy (SBRT) to medically unfit patients with unresectable head and neck cancers (HNCs). METHODS: A retrospective review of HNC patients undergoing SBRT was undertaken from 2011 to 2016 for fractionation ranges between 35 and 50 Gy in 4 to 6 fractions. RESULTS: One hundred and fourteen patients with 117 SBRT courses were included with mean follow-up of 10.5 months. The cohort consisted of previously untreated primary HNC (n = 48), recurrent never irradiated HNC (n = 19), oligometastatic (n = 17) non-HNC primaries and previously irradiated HNC (n = 33). Local control (LC) at 12 months and median progression free survival was 85.8%, 78.2%, 85%, 78.9% (P = .86) and 23.7, 14.8, 10.5 and 7.8 months (P = .04) respectively. Only one patient had an acute grade 4 toxicity, two patients had grade 4 late toxicities. CONCLUSIONS: HNC SBRT is an effective treatment for frail patients where longer LC is relevant but are unable to tolerate protracted radiation schedules.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Al-Assaf H, Erler D, Karam I, et al. Stereotactic body radiotherapy for medically unfit patients with cancers to the head and neck. Head Neck. 2020. PMID: 32199031. doi:10.1002/hed.26138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。